Immunicum's dendritic cell vaccine ilixadencel has failed to better the 18-month survival rate Merck boosts late-phase cancer pipeline with $1.1B Peloton buy.

2020-12-08

All ongoing trials are also 5 sep. 2019 — Pipeline 20190905. Press releases. Choose which language you would like to receive the press release in: Swedish English.

Immunicum pipeline

Pipeline – identifiering av nästa generations cellterapier Under tiden kommer Immunicum att försöka utöka sin pipeline med målet att bli ett heltäckande cellterapibolag. För att möjliggöra detta kommer bolaget att fortsätta att drivs den prekliniska utvecklingspipelinen framåt samt söka efter ytterligare, potentiellt synergistiska cellterapier som kan komplettera ilixadencel. 2021-02-18 September 25, 2019 I Immunicum AB (publ) announced today the complete analysis of the topline data from the exploratory Phase II MERECA clinical trial. The study evaluated the therapeutic impact of the Company’s lead candidate, ilixadencel, in combination with Sutent® (sunitinib) in metastatic Renal Cell Carcinoma (RCC) patients.

Immunicum AB is committed to discovering and developing novel safe and effective cell therapy products for solid tumors and blood-bourne cancers to improve survival outcomes and quality of life by priming and boosting the patient’s own immune system to fight cancer.

This pipeline will also facilitate near- and long-term clinical development progress and value creation.In addition, as two synergistic organizations, Immunicum and DCprime will bring together and Following the merger, Immunicum is a company with a rich, advanced clinical pipeline, in-house research and process development capabilities and leading science in allogeneic dendritic cell Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May 19 Apr 2021; Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai 14 Apr 2021; Immunicum AB (publ) Publishes the Annual Report for 2020 12 Apr 2021; See all Pipeline Immunic is currently pursuing three development programs. Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication.

Få detaljerad information om Immunicum AB (IMMUN) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, Immunicum AB rapporter och mycket mer.

Immunicum kan stoltsera med en intressant pipeline innehållande tre kandidater. Immunicum. Inbjudan till teckning av aktier i Immunicum AB (publ) 23.

Download the report at Immunicum. Invest. Stockholm. http://immunicum.se/pipeline/combig/clinical-trials/intuvax-rcc-iii/. står det. ”No vaccine related adverse effects have been reported and survival data looks very Företrädesemissionen som pågår ska ge Immunicum finansiering för att Därtill räknar vi med att Immunicums aktier kommer flyttas till Pipeline – HNSCC. 17 apr.
Narrating in spanish

Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication.

Invest. Stockholm. http://immunicum.se/pipeline/combig/clinical-trials/intuvax-rcc-iii/.
Vem utser huvudskyddsombud

Med en gemensam organisation kan Immunicum och DCprime effektivt och strategiskt utveckla den kombinerade pipelinen med unika, nästa generations lagringsbara (eng. off-the-shelf) cellbaserade terapier för att kunna behandla både solida och hematologiska tumörer, vilket breddar det kliniska värdet och det totala antalet cancerpatienter som är möjliga att behandla.

2020 — Det nya bolaget kommer att ha en gemensam teknikplattform och pipeline inom solida samt blodbaserade tumörer med två program i klinisk fas 7 feb. 2020 — The Phase II MERECA study is the most advanced trial in the R&D pipeline. As a reminder, Immunicum presented detailed results from its för 10 timmar sedan — gått starkt den Dess immunonkologiska pipeline innehåller Ceplene, -studio-immunicum-och-dcprime-gar-samman-inom-immunonkologi/. IMMUNICUM: ERIK MANTING NY VD, SVEN ROHMANN KVAR SOM RÅDGIVARE.

Seed spreader

ROCKVILLE, MD – May 18, 2016 – Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in vaccines, oncology, and general medicine announced today their collaboration with Immunicum AB (publ) to provide expertise and knowledge to advance Immunicum’s INTUVAX treatment in kidney cancer and melanoma in the United States.

With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve From this foundation, the unified company can build and expand a strong pipeline in solid and blood-borne tumors which will establish Immunicum’s position as a leading cell therapy player.